Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €91.30 EUR
Change Today -2.00 / -2.14%
Volume 180.0
SANF On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 4:01 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SANF) Snapshot

Open
€91.50
Previous Close
€93.30
Day High
€91.50
Day Low
€91.30
52 Week High
04/13/15 - €99.30
52 Week Low
10/29/14 - €69.65
Market Cap
119.4B
Average Volume 10 Days
785.0
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
05/11/15
P/E TM
--
Dividend
€2.85
Dividend Yield
3.12%
Current Stock Chart for SANOFI (SANF)

sanofi (SANF) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi (SANF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi (SANF) Key Developments

Sanofi Appoints Suresh Kumar to the Executive Committee and Executive Vice President, External Affairs, Effective from June 1, 2015

Sanofi announced the appointment of Suresh Kumar as a new member of the Executive Committee, effective June 1, 2015. Mr. Kumar joins Sanofi from Oliver Wyman and will take the position of Executive Vice President, External Affairs. In this newly created role, Mr. Kumar will be responsible for defining Sanofi`s vision for meeting global health challenges. This will include setting the strategy and priorities for public affairs activities, interactions with governments and international organizations - and aligning internal and external communications around these priorities. As part of bringing these activities together in a more integrated way, the Communications and Corporate Social Responsibility teams will report to Mr. Kumar. Since 2013, Mr. Kumar has served as a Partner with Oliver Wyman leading the firm`s Public Sector Practice and as part of the Health and Life Sciences Team.

Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference

Regeneron Pharmaceuticals, Inc. and Sanofi shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA). As previously reported, the study met its primary endpoint of improving lung function in asthma patients with high blood eosinophil counts (HEos, greater than or equal to 300 eosinophilic cells/microliter). Such high counts are thought to be a marker for patients more likely to have "atopic" or "allergic" asthma. New data presented on secondary endpoints at the American Thoracic Society 2015 International Conference included positive results in study patients with low blood eosinophil counts (LEos, less than 300 eosinophilic cells/microliter), who are thought to be less likely to suffer from "allergic" asthma and thus less likely to respond to TH2 targeted therapies. Dupilumab is an investigational therapy that inhibits signaling of IL-4 and IL-13, two cytokines required for the TH2 (or Type 2) immune response. Based on discussions with the U.S. Food and Drug Administration (FDA), this Phase 2b study may be considered one of two pivotal efficacy studies required for a potential dupilumab biologics license application (BLA) in asthma. The companies also announced the initiation of a Phase 3 clinical trial of dupilumab in patients with uncontrolled persistent asthma, known as LIBERTY ASTHMA QUEST, which will serve as the second required pivotal efficacy study. The global, placebo-controlled Phase 3 study will enroll more than 1,600 patients with uncontrolled persistent asthma and will evaluate two doses of dupilumab, 200 milligrams (mg) and 300 mg, subcutaneously administered every other week (Q2W). The new results focused on LEos asthma patients. In this population, patients treated with either 200 mg or 300 mg Q2W doses of dupilumab showed a greater than 8% improvement in forced expiratory volume over one second (FEV1, a standard measure of lung function) at Week 12 (p less than 0.001), in comparison to placebo, both in combination with ICS/LABA. Additionally, the 200 mg and 300 mg Q2W doses of dupilumab in combination with ICS/LABA showed 68% and 62% reductions, respectively, in adjusted annualized rate of severe exacerbations in the LEos population (p less than 0.01 and p less than 0.05), in comparison to placebo in combination with ICS/LABA. These results are consistent with previously reported positive results in HEos asthma patients and the overall patient population, in which the two Q2W doses (200 mg and 300 mg) of dupilumab in combination with ICS/LABA demonstrated a statistically significant 12 to 15% improvement in FEV1 over placebo at Week 12 and a 64 to 75% improvement in annualized rate of severe exacerbations over placebo. Dupilumab also significantly reduced mean fractional exhaled nitric oxide (FeNO) across both Q2W doses tested (200 and 300 mg) and the three patient populations (overall, LEos and HEos), in a roughly dose-dependent manner. FeNO is recommended by the American Thoracic Society clinical practice guidelines to assess airway inflammation, since higher than normal levels of nitric oxide may be released when a patient has a chronic airway disease, such as asthma. The most common adverse event was injection site reaction, which was more frequent in the dupilumab dose groups (13 to 25%) compared to placebo (12%). Other common adverse events in the study included upper respiratory tract infection (10 to 13% dupilumab; 13% placebo), headache (5 to 10% dupilumab; 8% placebo), nasopharyngitis (3 to 10% dupilumab; 6% placebo) and bronchitis (5 to 8% dupilumab; 8% placebo). The incidence of infections was balanced across treatment groups (42 to 45% dupilumab; 46% placebo), as was the incidence of serious adverse events (3 to 7% dupilumab; 5% placebo).

Sanofi Approves Amendment of Articles of Association

Sanofi announced that it approved amendment of Article 19 of the Articles of Association.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANF:IM €91.30 EUR -2.00

SANF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $157.35 USD -3.09
Bayer AG €131.25 EUR -2.27
Bristol-Myers Squibb Co $69.15 USD +0.75
GlaxoSmithKline PLC 1,474 GBp +14.00
Medtronic PLC $77.21 USD -0.11
View Industry Companies
 

Industry Analysis

SANF

Industry Average

Valuation SANF Industry Range
Price/Earnings 29.2x
Price/Sales 3.5x
Price/Book 2.2x
Price/Cash Flow 18.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.